Acumen Pharmaceuticals IncNASDAQ:ABOS
- LAST PRICE3.2700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.2300/ 6
- Ask / Lots3.4000/ 1
- Open / Previous Close--- / 3.2700
- Day Range---
- 52 Week Range
- Volume199
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABOS |
|---|---|---|
| 09:32 ET | 2602 | 3.25 |
| 09:33 ET | 8986 | 3.19 |
| 09:39 ET | 648 | 3.19 |
| 09:42 ET | 100 | 3.17 |
| 09:46 ET | 1300 | 3.15 |
| 09:48 ET | 721 | 3.22 |
| 09:51 ET | 200 | 3.2 |
| 09:53 ET | 648 | 3.1999 |
| 09:57 ET | 647 | 3.19 |
| 10:02 ET | 100 | 3.19 |
| 10:04 ET | 800 | 3.21 |
| 10:08 ET | 132 | 3.21 |
| 10:09 ET | 200 | 3.185 |
| 10:13 ET | 200 | 3.18 |
| 10:15 ET | 756 | 3.2 |
| 10:18 ET | 100 | 3.21 |
| 10:20 ET | 100 | 3.21 |
| 10:27 ET | 400 | 3.19 |
| 10:29 ET | 2502 | 3.195 |
| 10:31 ET | 250 | 3.1936 |
| 10:33 ET | 100 | 3.19 |
| 10:36 ET | 500 | 3.21 |
| 10:40 ET | 350 | 3.2077 |
| 10:45 ET | 350 | 3.2099 |
| 10:49 ET | 100 | 3.2 |
| 10:51 ET | 300 | 3.19 |
| 10:56 ET | 100 | 3.2 |
| 11:02 ET | 300 | 3.18 |
| 11:03 ET | 400 | 3.18 |
| 11:05 ET | 100 | 3.18 |
| 11:07 ET | 200 | 3.19 |
| 11:09 ET | 986 | 3.2 |
| 11:14 ET | 338 | 3.1901 |
| 11:16 ET | 230 | 3.2 |
| 11:18 ET | 100 | 3.21 |
| 11:23 ET | 1576 | 3.22 |
| 11:25 ET | 100 | 3.23 |
| 11:27 ET | 100 | 3.23 |
| 11:36 ET | 680 | 3.23 |
| 11:38 ET | 213 | 3.2355 |
| 11:48 ET | 1613 | 3.22 |
| 11:50 ET | 906 | 3.2203 |
| 11:52 ET | 200 | 3.24 |
| 11:54 ET | 100 | 3.25 |
| 11:59 ET | 399 | 3.23 |
| 12:03 ET | 505 | 3.23 |
| 12:08 ET | 100 | 3.23 |
| 12:10 ET | 100 | 3.23 |
| 12:12 ET | 100 | 3.23 |
| 12:14 ET | 3802 | 3.21 |
| 12:24 ET | 844 | 3.22 |
| 12:28 ET | 260 | 3.225 |
| 12:30 ET | 100 | 3.22 |
| 12:39 ET | 100 | 3.22 |
| 12:42 ET | 100 | 3.22 |
| 12:44 ET | 317 | 3.22 |
| 12:55 ET | 100 | 3.22 |
| 12:57 ET | 651 | 3.24 |
| 01:00 ET | 1617 | 3.24 |
| 01:02 ET | 100 | 3.245 |
| 01:04 ET | 100 | 3.245 |
| 01:06 ET | 398 | 3.245 |
| 01:09 ET | 500 | 3.2412 |
| 01:11 ET | 400 | 3.24 |
| 01:18 ET | 948 | 3.23 |
| 01:20 ET | 3152 | 3.23 |
| 01:22 ET | 200 | 3.23 |
| 01:24 ET | 100 | 3.23 |
| 01:29 ET | 3023 | 3.25 |
| 01:31 ET | 100 | 3.25 |
| 01:38 ET | 400 | 3.25 |
| 01:40 ET | 200 | 3.25 |
| 01:44 ET | 100 | 3.25 |
| 01:45 ET | 5267 | 3.26 |
| 01:47 ET | 100 | 3.25 |
| 01:54 ET | 100 | 3.25 |
| 01:56 ET | 100 | 3.25 |
| 01:58 ET | 6629 | 3.29 |
| 02:00 ET | 6918 | 3.28 |
| 02:02 ET | 1349 | 3.27 |
| 02:03 ET | 100 | 3.26 |
| 02:05 ET | 500 | 3.26 |
| 02:07 ET | 200 | 3.26 |
| 02:09 ET | 300 | 3.25 |
| 02:14 ET | 533 | 3.25 |
| 02:18 ET | 100 | 3.255 |
| 02:20 ET | 3020 | 3.24 |
| 02:23 ET | 100 | 3.24 |
| 02:25 ET | 100 | 3.24 |
| 02:30 ET | 1050 | 3.25 |
| 02:34 ET | 2349 | 3.27 |
| 02:36 ET | 229 | 3.265 |
| 02:41 ET | 100 | 3.265 |
| 02:43 ET | 100 | 3.265 |
| 02:50 ET | 100 | 3.27 |
| 02:52 ET | 5035 | 3.27 |
| 02:54 ET | 3000 | 3.26 |
| 02:57 ET | 100 | 3.26 |
| 03:01 ET | 400 | 3.26 |
| 03:03 ET | 200 | 3.26 |
| 03:10 ET | 815 | 3.27 |
| 03:12 ET | 100 | 3.26 |
| 03:14 ET | 100 | 3.26 |
| 03:15 ET | 200 | 3.26 |
| 03:17 ET | 200 | 3.26 |
| 03:19 ET | 402 | 3.2599 |
| 03:21 ET | 553 | 3.255 |
| 03:24 ET | 100 | 3.255 |
| 03:26 ET | 400 | 3.26 |
| 03:28 ET | 1881 | 3.27 |
| 03:32 ET | 200 | 3.265 |
| 03:33 ET | 4756 | 3.27 |
| 03:35 ET | 2780 | 3.265 |
| 03:37 ET | 100 | 3.265 |
| 03:42 ET | 700 | 3.265 |
| 03:44 ET | 208 | 3.265 |
| 03:46 ET | 1570 | 3.27 |
| 03:48 ET | 1459 | 3.255 |
| 03:50 ET | 200 | 3.25 |
| 03:51 ET | 100 | 3.255 |
| 03:53 ET | 1284 | 3.26 |
| 03:55 ET | 1053 | 3.26 |
| 03:57 ET | 828 | 3.27 |
| 04:00 ET | 21620 | 3.27 |
Nov 6, 2024
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference, from 4:00PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:00PM ET on Wednesday Nov 06, 2024 by Dow JonesPress Release: Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow JonesAcumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024, from 4:00PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:00PM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 31, 2024
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference, from 8:05AM ET on Thursday Oct 31, 2024 by Dow Jones
8:05AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acumen Pharmaceuticals Inc | 196.5M | -2.9x | --- |
Gossamer Bio Inc | 198.8M | -2.7x | --- |
Instil Bio Inc | 200.6M | -1.7x | --- |
Greenwich Lifesciences Inc | 189.2M | -18.1x | --- |
Atossa Therapeutics Inc | 188.6M | -7.3x | --- |
Inhibikase Therapeutics Inc | 189.4M | -1.0x | --- |
Company Information
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.
Contact Information
- Headquarters
- 427 PARK ST.CHARLOTTESVILLE, VA, United States 22902
- Phone
- 925-368-8508
- Fax
- 302-636-5454
Executives
- President, Chief Development Officer
- James Doherty
- Chief Executive Officer, Director
- Daniel O'Connell
- Chief Financial Officer, Chief Business Officer
- W. Matthew Zuga
- Chief Operating Officer
- Russell Barton
- Chief Legal Officer
- Derek Meisner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $196.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 60.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.10 |
EPS | $-1.11 |
Book Value | $4.61 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
